Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.
At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.
The DISCOVER Trial, a Phase 3 Study Shows Results In Descovy (TAF/FTC) As An Effective Alternative To Truvada (TDF/FTC).
The DISCOVER trial was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.